ArticleJournal of veterinary internal medicine2021
Frunevetmab, a felinized anti-nerve growth factor monoclonal antibody, for the treatment of pain from osteoarthritis in cats.
Article in Journal of veterinary internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 46 citations in OpenAlex.
- Pilot study demonstrating safety and efficacy of intravenous allogeneic uterine-derived mesenchymal stromal cell therapy in cats with naturally occurring osteoarthritis.Frontiers in veterinary science · 2026Trial
- Prospective, randomized, placebo-controlled, multicenter, double-blind, parallel-group, registration field trial evaluating izenivetmab, a caninized anti-nerve growth factor monoclonal antibody, administered quarterly to dogs with naturally occurring osteoarthritis.Veterinary and animal science · 2026Article
- Therapeutic Monoclonal Antibodies as Advanced Therapies for Companion Animals: Species Adaptation, Fc Biology, Clinical Translation, and Future Platforms.Veterinary sciences · 2026Review
- Client experience and owner-reported functional recovery after feline orthopedic surgery: A structural equation model of loyalty and recommendation intentions.Open veterinary journal · 2026Article
- Safety assessment of frunevetmab for osteoarthritis pain in cats: disproportionality analysis of the Food and Drug Administration Animal Drug Adverse Events database.Journal of veterinary internal medicine · 2026Article
- Veterinarians' brief guide to confidence intervals, standardized effect size, and number needed to treat: understanding the impact of treatments and disease.Frontiers in veterinary science · 2026Article
- Flow cytometric evaluation of monoclonal antibodies for cross-reactivity with feline leukocytes.Frontiers in veterinary science · 2026Article
- Beyond Osteoarthritis: Emerging Applications of Anti-NGF Monoclonal Antibodies in Pain Management in Dogs and Cats.Animals : an open access journal from MDPI · 2025Review
- Field safety and efficacy study with a cannabidiol/cannabidiol acid-rich hemp paste in cats with osteoarthritic pain.Journal of feline medicine and surgery · 2025Article
- Clinical therapeutics in feline medicine: updates for old and new drugs.Journal of feline medicine and surgery · 2025Review
- Intraarticular resiniferatoxin, a potent TRPV1 agonist, for treatment of osteoarthritic pain.Pain management · 2025Review
- Osteoarthritis in cats: what we know, and mostly, what we don't know. . . yet.Journal of feline medicine and surgery · 2025Review
- Unveiling the Future: Opportunities in Long-Acting Injectable Drug Development for Veterinary Care.Pharmaceutics · 2025Review
- Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs.Journal of pharmacokinetics and pharmacodynamics · 2024Article
- Evaluation of stem-cell therapies in companion animal disease models: a concise review (2015-2023).Stem cells (Dayton, Ohio) · 2024Review
- First site-specific conjugation method for native goat IgG antibodies via glycan remodeling at the conserved Fc region.Antibody therapeutics · 2024Article
- Neuropathic pain in cats: Mechanisms and multimodal management.Journal of feline medicine and surgery · 2024Review
- 2024 ISFM and AAFP consensus guidelines on the long-term use of NSAIDs in cats.Journal of feline medicine and surgery · 2024Article
- Concurrent Validation of MI-CAT(V), a Clinical Metrology Instrument for Veterinarians Assessing Osteoarthritis Pain in Cats, through Testing for Firocoxib Analgesic Efficacy in a Prospective, Randomized, Controlled, and Blinded Study.Animals : an open access journal from MDPI · 2024Article
- Cutaneous lesions and clinical outcomes in five cats after frunevetmab injections.Journal of feline medicine and surgery · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundFrunevetmab, a felinized antinerve growth factor monoclonal antibody, effectively decreases osteoarthritis (OA) pain in cats.
objectiveTo evaluate the efficacy of frunevetmab given at monthly intervals in a randomized, placebo-controlled, parallel-group, double-blind superiority study. ANIMALS: Two hundred seventy-five client-owned cats with naturally-occurring OA pain and associated mobility impairment and disability.
methodsRandomized, placebo-controlled, parallel-group, double-blind, superiority study. Following screening, cats received frunevetmab (nominal dose of 1.0 mg/kg, SC [effective dose range of 1.0-2.8 mg/kg]) or placebo on days 0, 28, and 56. Outcome measures were owner questionnaires and veterinary physical and orthopedic evaluations at days 28, 56, and 84. Success/failure rates (and numbers needed treat, NNT) and change in scores (and standardized effect size, ES) were analyzed.
resultsFrunevetmab (182) and placebo (93) treated cats were enrolled and received at least 1 treatment. Significant improvement with frunevetmab over placebo occurred at days 28 and 56 for the client specific outcome measures (CSOM) questionnaire (success rates and total scores [NNT of 9 and ES of 0.3 at day 56]); at days 28 and 56 for owner-assessed global treatment response; and at days 56 and 84 for veterinarian-assessed joint pain (ES of 0.18 at day 56). Adverse events did not differ between groups, except skin disorders which collectively occurred significantly more frequently in frunevetmab treated (32/182 cats) vs placebo (8/93 cats). CONCLUSIONS AND CLINICAL IMPORTANCE: Frunevetmab has the potential to address a critical gap in the treatment of pain because of osteoarthritis in cats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.